USPTO Examiner MCGARRY SEAN - Art Unit 1635

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19323583COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDSeptember 2025October 2025Allow200NoNo
19196434IDENTIFICATION OF MICRORNA BIOMARKERS FOR DIAGNOSIS AND TREATMENT FOR SLEEP APNEAMay 2025October 2025Allow600NoNo
18982078Therapeutic Compounds for Red Blood Cell-Mediated Delivery of an Active Pharmaceutical Ingredient to a Target CellDecember 2024September 2025Allow911NoNo
18887946COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDSeptember 2024March 2025Allow620NoNo
18819435MODELS OF TAUOPATHYAugust 2024April 2025Allow810NoNo
18774194Pan-Genotypic Agents Against Influenza Virus and Methods of Using the SameJuly 2024January 2026Allow1811NoNo
18765750SAMPLE SPLITTING FOR MULTIPLEXED DETECTION OF NUCLEIC ACIDS WITHOUT AMPLIFICATIONJuly 2024February 2025Allow710NoNo
18738165STEROL REGULATORY ELEMENT BINDING PROTEIN (SREBP) CHAPERONE (SCAP) iRNA COMPOSITIONS AND METHODS OF USE THEREOFJune 2024November 2025Allow1701NoNo
18673713TRANS-SPLICING MOLECULESMay 2024June 2025Allow1300NoNo
18662046Antisense Nucleic AcidsMay 2024October 2025Abandon1720NoNo
18655096SINGLE-STRANDED RNA-EDITING OLIGONUCLEOTIDESMay 2024October 2025Allow1710NoNo
18623472STAUFEN1 REGULATING AGENTS AND ASSOCIATED METHODSApril 2024October 2025Allow1920NoNo
18608561METHODS AND COMPOSITIONS FOR SENSITIZATION OF TUMOR CELLS TO IMMUNE THERAPYMarch 2024September 2025Allow1811NoNo
18599942METHODS AND COMPOSITIONS FOR INHIBITING PMP22 EXPRESSIONMarch 2024September 2025Allow1820YesNo
18441280COMPOSITIONS AND THERAPEUTIC METHODS OF MICRORNA GENE DELIVERYFebruary 2024April 2025Allow1410NoNo
18407780Therapeutic Compounds for Red Blood Cell-Mediated Delivery of an Active Pharmaceutical Ingredient to a Target CellJanuary 2024September 2024Allow810NoNo
18407815Therapeutic Compounds for Red Blood Cell-Mediated Delivery of an Active Pharmaceutical Ingredient to a Target CellJanuary 2024March 2024Allow200NoNo
18406159SAMPLE SPLITTING FOR MULTIPLEXED DETECTION OF NUCLEIC ACIDS WITHOUT AMPLIFICATIONJanuary 2024June 2024Allow600NoNo
18392181Methods Of Treating Decreased Bone Mineral Density With Cluster Of Differentiation 109 (CD109) InhibitorsDecember 2023October 2024Allow1010NoNo
18512207Aptamers For Personal Health Care ApplicationsNovember 2023March 2025Allow1620NoNo
18511108DNA Monoclonal Antibodies Targeting Influenza VirusNovember 2023May 2025Allow1820NoNo
18503125SOLUBLE INTERLEUKIN-7 RECEPTOR (SIL7R) MODULATING THERAPY TO TREAT AUTOIMMUNE DISEASES AND CANCERNovember 2023March 2025Allow1620NoNo
18502516MODELS OF TAUOPATHYNovember 2023June 2024Allow700NoNo
18489316MODULATION OF PREKALLIKREIN (PKK) EXPRESSIONOctober 2023December 2025Allow2511NoNo
18381238DOSAGES AND METHODS FOR DELIVERING LIPID FORMULATED NUCLEIC ACID MOLECULESOctober 2023December 2024Abandon1401NoNo
18380695ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOFOctober 2023July 2025Allow2121NoNo
18487429SOLUBLE INTERLEUKIN-7 RECEPTOR (SIL7R) MODULATING THERAPY TO TREAT AUTOIMMUNE DISEASES AND CANCEROctober 2023November 2024Allow1320NoNo
18485724COMPOUNDS AND METHODS FOR REDUCING ATXN3 EXPRESSIONOctober 2023August 2025Allow2201NoNo
18368248APPARATUS, METHOD, AND USE FOR ULTRASOUND MEDIATED MICROBUBBLE DELIVERY OF PHARMACEUTICAL COMPOSITIONSSeptember 2023October 2024Abandon1301NoNo
18450033VIRAL VECTOR PRODUCTIONAugust 2023February 2025Allow1810NoNo
18448254METHODS FOR PRODUCTION OF MSC-DERIVED EXOSOMESAugust 2023June 2025Allow2211NoNo
18360143USE OF ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, MEMBER A5 ANTIBODIES FOR THE TREATMENT OF GLAUCOMAJuly 2023July 2025Allow2411NoNo
18356404Methods for Treatment of Alport SyndromeJuly 2023October 2024Abandon1510NoNo
18345452ANGELMAN SYNDROME ANTISENSE TREATMENTJune 2023September 2024Allow1420NoNo
18342409CONJUGATED ANTISENSE COMPOUNDS AND THEIR USEJune 2023December 2024Allow1810NoNo
18330084Compositions for Modulating C9ORF72 ExpressionJune 2023October 2025Allow2911YesNo
18205390NUCLEOLIN-TARGETING APTAMERS AND METHODS OF USING THE SAMEJune 2023January 2025Allow2011NoNo
18204441PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) iRNA COMPOSITIONS AND METHODS OF USE THEREOFJune 2023October 2025Allow2911NoNo
18316556Albumin Production and Cell ProliferationMay 2023September 2024Abandon1610NoNo
18315890MODULATING APOLIPOPROTEIN (A) EXPRESSIONMay 2023April 2025Allow2420NoNo
18310289MODULATORS AND MODULATION OF THE RECEPTOR FOR ADVANCED GLYCATION END-PRODUCTS RNAMay 2023January 2026Allow3210NoNo
18296912SINGLE-STRANDED RNA-EDITING OLIGONUCLEOTIDESApril 2023November 2023Allow710NoNo
18128949ANTIDOTE-MEDIATED REVERSAL OF EXTRACELLULAR APTAMER STAININGMarch 2023May 2025Allow2510NoNo
18168066Screening artificial nucleic acids by particle displayFebruary 2023February 2025Allow2412NoNo
18165113SELECTIVE INHIBITION OF T FOLLICULAR HELPER CELLS FOR TREATMENT OF AUTOIMMUNE DISORDERSFebruary 2023August 2024Allow1810NoNo
18155945COMPOSITIONS FOR MODULATING TAU EXPRESSIONJanuary 2023March 2024Allow1410NoNo
18013055Blood-Brain Barrier Penetrating Aptamer and Use ThereofDecember 2022August 2025Allow3200NoNo
18065739APTAMERS FOR PERSONAL HEALTH CARE APPLICATIONSDecember 2022December 2025Allow3610NoNo
18065655APTAMERS FOR PERSONAL HEALTH CARE APPLICATIONSDecember 2022December 2025Allow3610NoNo
18065652APTAMERS FOR PERSONAL HEALTH CARE APPLICATIONSDecember 2022November 2025Allow3510NoNo
18065723APTAMERS FOR PERSONAL HEALTH CARE APPLICATIONSDecember 2022December 2025Allow3610NoNo
18080049METHOD FOR TREATING CARDIOVASCULAR DISEASEDecember 2022November 2024Abandon2320NoNo
17927742MONOCYTE-SPECIFIC APTAMERS AND USES THEREOF FOR ENHANCING DRUG DELIVERY TO CANCERNovember 2022October 2025Allow3500NoNo
17991955Compositions and Methods for Modulation of SMN2 Splicing in a SubjectNovember 2022February 2026Abandon3901NoNo
18057050Therapeutic Compounds for Red Blood Cell-Mediated Delivery of an Active Pharmaceutical Ingredient to a Target CellNovember 2022September 2025Allow3411NoNo
18055525METHODS AND COMPOSITIONS FOR THE ACTIVATION OF GAMMA-DELTA T-CELLSNovember 2022April 2025Allow2911NoNo
18055212ANGLEMAN SYNDROME ANTISENSE TREATMENTNovember 2022June 2023Allow720NoNo
18053679ANTISENSE NUCLEIC ACIDSNovember 2022October 2024Abandon2310NoNo
17982469C5a Binding Nucleic AcidsNovember 2022August 2024Allow2200NoNo
18051821METHODS AND COMPOSITIONS FOR THE ACTIVATION OF GAMMA-DELTA T-CELLSNovember 2022May 2025Allow3011NoNo
18051487AMPHIPHILIC POLYNUCLEOTIDESOctober 2022December 2023Allow1301NoNo
18045357TREATING METASTATIC CANCER AND MODEL SYSTEMS FOR METASTATIC DISEASEOctober 2022March 2024Allow1710NoNo
17930364MODULATORS AND MODULATION OF THE RECEPTOR FOR ADVANCED GLYCATION END-PRODUCTS RNASeptember 2022January 2023Allow510NoNo
17895007ANTICANCER COMPOSITIONS AND METHODS FOR MAKING AND USING THEMAugust 2022February 2024Allow1810NoNo
17892686COMPOSITIONS AND METHODS FOR IDENTIFYING POLYNUCLEOTIDES OF INTERESTAugust 2022May 2024Allow2001NoNo
17878433Pan-Genotypic Agents Against Influenza Virus and Methods of Using the SameAugust 2022September 2025Allow3701NoNo
17816084Methods Of Treating Decreased Bone Mineral Density With Cluster Of Differentiation 109 (CD109) InhibitorsJuly 2022September 2023Allow1410NoNo
17816059MTOR-INHIBITOR-CONTAINING MEDICINE FOR TREATING OR PREVENTING OPHTHALMIC SYMPTOMS, DISORDERS, OR DISEASES, AND APPLICATION THEREOFJuly 2022March 2025Allow3121NoNo
17812576TRANSLATABLE MOLECULES AND SYNTHESIS THEREOFJuly 2022November 2023Allow1610NoNo
17861676METHOD FOR REDUCING THE EXPRESSION OF NKCC1 IN A SUBJECTJuly 2022July 2024Abandon2510NoNo
17860141STEROL REGULATORY ELEMENT BINDING PROTEIN (SREBP) CHAPERONE (SCAP) iRNA COMPOSITIONS AND METHODS OF USE THEREOFJuly 2022June 2024Abandon2401NoNo
17852939Compounds and Methods for Reducing ATXN3 ExpressionJune 2022July 2023Allow1200NoNo
17849294TWIST SIGNALING INHIBITOR COMPOSITIONS AND METHODS OF USING THE SAMEJune 2022October 2023Allow1610NoNo
17844877Heterologous UTR Sequences for Enhanced mRNA ExpressionJune 2022January 2024Allow1801NoNo
17746387METHODS OF INDUCING INSULIN PRODUCTIONMay 2022April 2024Abandon2301NoNo
17775136EXON SKIPPING OF FC-EPSILON-RI-BETA AND MS4A6A IN COMBINATION FOR THE TREATMENT OF ALLERGIC DISEASESMay 2022January 2026Allow4510NoNo
17773461METHOD FOR PRODUCING NUCLEIC ACID MOLECULE, BIOMATERIAL, AND METHOD FOR PRODUCING BIOMATERIALApril 2022December 2025Allow4410NoNo
17772549Allele-specific silencing therapy for DFNA9 using antisense oligonucleotidesApril 2022October 2025Allow4210NoNo
17772128FUNCTIONAL LIGANDS TO SARS-COV-2 SPIKE PROTEINApril 2022January 2026Abandon4410NoNo
17724176COMPOSITIONS AND METHODS FOR INHIBITING NUCLEAR RECEPTOR SUBFAMILY 1 GROUP H MEMBER 3 (NR1H3) EXPRESSIONApril 2022July 2022Allow300NoNo
17716497Pan-Genotypic Agents Against Influenza Virus and Methods of Using the SameApril 2022August 2024Abandon2801NoNo
17767349APTAMER BASED SYSTEM TO QUANTIFY ANTI-THROMBIN III IN BLOODApril 2022February 2026Allow4611NoNo
17714196ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOFApril 2022June 2022Allow200NoNo
17766013Nucleic Acid Compounds that Bind to Retinoic Acid-Inducible Gene I ProteinApril 2022December 2025Abandon4401NoNo
17694482CD44 APTAMERMarch 2022July 2023Allow1601NoNo
17692048METHODS AND COMPOSITIONS TO DIRECT BREAKDOWN OF INSULIN MRNA IN BENIGN FASHIONMarch 2022May 2025Abandon3821NoNo
17668504INHIBITION OF KMT2D FOR THE TREATMENT OF CANCERFebruary 2022May 2023Allow1500NoNo
17569658THERAPEUTIC ALTERATION OF TRANSPLANTABLE TISSUES THROUGH IN SITU OR EX VIVO EXPOSURE TO RNA INTERFERENCE MOLECULESJanuary 2022May 2024Allow2820YesNo
17570313COMBINATION VECTORS AND METHODS FOR TREATING CANCERJanuary 2022March 2025Allow3812NoNo
17645895APPLICATION OF AGENT IN PREPARATION OF MEDICINE FOR TREATING/INHIBITING PSORIASISDecember 2021April 2025Abandon4021NoNo
17619712METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCERDecember 2021December 2025Allow4811NoNo
17615621METHODS FOR MODULATING IMMUNOGLOBULIN EXPRESSIONDecember 2021October 2025Abandon4601NoNo
17531900ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOFNovember 2021March 2022Allow310NoNo
17531919ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOFNovember 2021July 2023Allow2010NoNo
17531888ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOFNovember 2021March 2022Allow310NoNo
17531921ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOFNovember 2021July 2023Allow2010NoNo
17531913ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOFNovember 2021July 2023Allow2010NoNo
17531885ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOFNovember 2021March 2022Allow310NoNo
17595576NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOFNovember 2021January 2026Abandon5011NoNo
17523456ANGELMAN SYNDROME ANTISENSE TREATMENTNovember 2021April 2023Allow1710NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MCGARRY, SEAN.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
3
Examiner Affirmed
2
(66.7%)
Examiner Reversed
1
(33.3%)
Reversal Percentile
49.2%
Lower than average

What This Means

With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
54
Allowed After Appeal Filing
14
(25.9%)
Not Allowed After Appeal Filing
40
(74.1%)
Filing Benefit Percentile
37.4%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 25.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner MCGARRY, SEAN - Prosecution Strategy Guide

Executive Summary

Examiner MCGARRY, SEAN works in Art Unit 1635 and has examined 958 patent applications in our dataset. With an allowance rate of 59.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 32 months.

Allowance Patterns

Examiner MCGARRY, SEAN's allowance rate of 59.9% places them in the 20% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by MCGARRY, SEAN receive 1.26 office actions before reaching final disposition. This places the examiner in the 17% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by MCGARRY, SEAN is 32 months. This places the examiner in the 49% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +25.6% benefit to allowance rate for applications examined by MCGARRY, SEAN. This interview benefit is in the 72% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 30.0% of applications are subsequently allowed. This success rate is in the 58% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 56.6% of cases where such amendments are filed. This entry rate is in the 83% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 92% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 90.9% of appeals filed. This is in the 83% percentile among all examiners. Of these withdrawals, 90.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 60.2% are granted (fully or in part). This grant rate is in the 64% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 9.6% of allowed cases (in the 93% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 5.9% of allowed cases (in the 83% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.